EUVIMEDEUVIMED entdecken
Crossref

Futibatinib (Lytgobi) for Cholangiocarcinoma

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1674f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oral kinase inhibitor futibatinib (Lytgobi – Taiho) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Accelerated approval was based on the overall response rate and duration of response. Futibatinib is the second drug to be approved for this indication; pemigatinib (Pemazyre) was approved earlier.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsHumansGemcitabineBile Ducts, IntrahepaticPyrazolesPyrimidinesPyrroles

Stichwörter der Autor:innen

Lytgobiadverse effectscholangiocarcinomacisplatindosagedrug interactionsefficacyfutibatinibgemcitabinelactationpregnancysafety

Substanzen

GemcitabinefutibatinibPyrazolesPyrimidinesPyrroles

Zitieren

APA

(2023). Futibatinib (Lytgobi) for Cholangiocarcinoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1674f

Vancouver

Futibatinib (Lytgobi) for Cholangiocarcinoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1674f

BibTeX
@article{euvimed2023,
  title = {Futibatinib (Lytgobi) for Cholangiocarcinoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1674f}
}
Kostenlos starten →